Beyond BRIC: 'Pharmerging' Markets Loom If Pharma Is To Expand, IMS Study Says
This article was originally published in PharmAsia News
Executive Summary
Drug makers need to more aggressively target so-called "pharmerging" markets - but not just the usual suspects. Brazil, Russia, India and China remain highly important, but in a March 16 report, IMS Health predicts that 17 countries, in total, will contribute 48 percent of annual market growth in 2013, up from 37 percent last year
You may also be interested in...
Pfizer Escapes Anti-Monopoly Ruling In Indonesia For Amlodipine
An Indonesian court reversed a year-old anti-monopoly ruling against Pfizer Inc. and four of its units, the first cartel case in the country involving the pharmaceutical industry
Pfizer Escapes Anti-Monopoly Ruling In Indonesia For Amlodipine
An Indonesian court reversed a year-old anti-monopoly ruling against Pfizer Inc. and four of its units, the first cartel case in the country involving the pharmaceutical industry
Vietnam Drug Authority Plan To Develop Local Drug Industry Is Mixed Bag For Foreign Drug Makers
The Vietnam Drug Administration has drafted a new master plan for developing its local drug industry that envisions supplying a majority of the country's demand for drugs from local drug makers by 2020-30